Company / Shareholders' Equity
Theravance Biopharma, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$296.7M
FY2025
5-year range
-$338.6M / $296.7M
FY2021-FY2025
Trend
+69.0%
vs FY2024
Sector context
#135 of 213
Health Care
What the data says
At $297M, Theravance Biopharma, Inc.'s shareholders' equity ranks #135 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from -$339M in FY2022 to $350M in FY2018.
Based on SEC 10-K filings.
$297M in FY2025.
Improved from $213M to $297M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#135 of 213 in Health CareTop 63% of 213This company $296.7M Sector average $2.5B
▼
-88.4% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 69.0% year-over-year.
- Ranks #135 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2018.
- Lowest shareholders' equity in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $296.7M | +69.0% |
| FY2024 | $175.5M | -17.6% |
| FY2023 | $213.0M | +162.9% |
| FY2022 | -$338.6M | +0.0% |
| FY2021 | -$338.6M | -11.5% |
| FY2020 | -$303.8M | -363.7% |
| FY2019 | $115.2M | -67.1% |
| FY2018 | $350.2M | +204.1% |
| FY2017 | $115.2M | -67.1% |
| FY2016 | $350.2M | +2155.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026